Immune Checkpoints

Join the only forum delving into how checkpoint combinations can impact every stage of the cancer immunity cycle. Enhance the long-term success of your IO drug development. See the exciting 3 day programme for #ICIEurope online today: bit.ly/2NYHclM #immunecheckpoint

Molecular Partners will argue the case for bispecifics, @Merck will share how they screen MDSCs to ID potential targets, and Arcus will define the logic behind TIGIT combinations. See the 3 day packed programme for #ICIEurope online today: bit.ly/2NYHclM

Why target innate lymphocytes? We ask @InnatePharma only at the 4th #ICIEurope Summit in Berlin this November. For this and more of your questions answered, visit the website to find out more: bit.ly/2NYHclM #immunecheckpoint

Meet us in Berlin this November for our 4th #ICIEurope Summit. NovImmune will be joining us again this year to share how they enhance #macrophage killing. Find out more: bit.ly/2NYHclM #immunecheckpoint

Hear from @genentech on ensuring the new crop of cancer vaccines are more personalised than ever before. Only at #ICIEurope Summit. Find out more: bit.ly/2NYHclM #ici #immunecheckpoint #personalisedvaccine #personalisedmedicine

Understand the reasons behind clinical anti-PD(L)1 failures and use this data to inform your future #IO strategy. Learn from failures, not just successes at the #ICIEurope Summit. View our recently finalised agenda for more info - bit.ly/2DgKNaA #immunecheckpoint #PD1

Dr Yan Lan Sr. Director @merckgroup @EMDSerono Amazing Talk! presents recent Sci Transl Med Jan 2018/M7824 targets TGFbeta & PD-L1/**SLIDE SET 1** @BMS_ImmunOnc_US @MedImmune @MacroGenics @genentech @pfizer @Merck #ICIBOS2018 @TakedaOncology

Nanobiotix: Nanobiotix' USA CEO @PatrickTricoli was invited to present at the 4th ICI Boston Summit : "NBTXR3: A New Modality Across the Board of Oncology" #Nanobiotix #ImmunoOncology @ici_checkpoint: Nanobiotix' USA CEO @PatrickTricoli was… dlvr.it/QLwV95 #MedicBoard

@Nanobiotix @PatrickTricoli @ici_checkpoint Great talk! Clear presentation of #nanobiotix and #NBTXR3

Nanobiotix' USA CEO @PatrickTricoli was invited to present at the 4th ICI Boston Summit : "NBTXR3: A New Modality Across the Board of Oncology" #Nanobiotix #ImmunoOncology @ici_checkpoint

Dr. John Burke presented on Predicting marketed PD-1 dosing and optimal PD-1 x TIM-3 dual targeting approaches in immuno-oncology @ici_checkpoint this morning. Look forward to meeting everyone at conference!

conference event: 4th annual ICI Boston Summit. 19-21 March 2018 Boston MA USA bit.ly/2DXi6Qc @ici_checkpoint #antibodies

HOW TO COMBINE #Immunotherapy? Next 8 days 2 meeting on topic 1) @ici_checkpoint in @CityOfBoston bit.ly/1Q3WTmM & 2) @DaveMess10 @boehringerus & I talk @KeystoneSymp in @montreal bit.ly/2pmpeLA @theNCI @BMS_ImmunOnc_US @MedImmune @Merck #FinishCancer @Roche twitter.com/thenci/status/…

Immunotherapy has revolutionized oncology, however, only a small percentage of patients currently benefit. Discover seven of its challenges in this exclusive editorial from @OncologyCentral : bit.ly/2nif51N

Uncover the true value of pathways beyond PD-1, including the rationale behind targeting CD47, A2R, TIM-3 and LAG-3, including potential future combination approaches, with perspectives from @Novartis. Learn more: bit.ly/2o6eAZx

Join us at #ICIBoston (March 19-21) for 30+ world leading expert speakers, 25+ hours of content, 4 interactive workshops and 3 days of networking dedicated solely to enhancing the success of your IO pipeline. Learn more: bit.ly/2o6eAZx

Immunotherapy has revolutionized oncology, however, only a small percentage of patients currently benefit. Discover seven of its challenges in this exclusive editorial from @OncologyCentral : bit.ly/2nif51N

Enabling successful collaborations is at the heart of #ICIBoston. Collaborate with 100+ leading minds in the IO space including companies such as @Merck @Novartis @BeiGeneUSA @EMDSerono @regeneron @JounceTx @AstraZenecaUS and @SeresTX. Find out more: bit.ly/2o6eAZx